Renal cell carcinoma (RCC) is the most common malignancy of the kidney, accounting for 2%--3% of all adult malignancies ([@bib19]). The risk factors for the development of RCC include obesity, hypertension, and cigarette smoking ([@bib5]). Increased body mass index (BMI), a commonly used index of obesity, is strongly associated with the development of RCC ([@bib18]). Paradoxically, increased BMI has also been associated with a favourable prognosis in patients with RCC ([@bib6]; [@bib15]; [@bib11]; [@bib4]).

Although several studies have indicated that women with RCC have a significantly lower BMI than men with RCC ([@bib6]; [@bib15]; [@bib11]), few studies have investigated the sex-related differences for the prognostic implications of BMI. In addition, several studies have demonstrated that women with RCC have better prognoses than men with RCC ([@bib1]; [@bib20]; [@bib13]). However, the better prognosis in women seems to be inconsistent with the relatively lower BMI in women with RCC than men with RCC. Thus, we assumed that there might be a sex-related difference in the prognostic value of BMI in patients with RCC. The aim of this study was to investigate the associations among sex, BMI, and prognosis in patients with RCC. As recent studies have reported obesity as a stronger risk factor for the clear cell subtype of RCC, compared with other subtypes ([@bib16]), only patients with clear cell RCC were examined.

Materials and methods
=====================

Patients
--------

This study was conducted according to the ethics guidelines for clinical studies of the Ministry of Health, Labour and Welfare in Japan and was approved by the ethics committee of our facility. The medical charts of 482 consecutive patients who had undergone nephrectomy at Tokyo Medical University Hospital between 1990 and 2009 were retrospectively reviewed; 435 patients, identified as having clear cell RCC using the seventh edition of the tumour-node-metastasis staging system ([@bib7]), were included in the study. Sixty patients underwent partial nephrectomy and 375 underwent total nephrectomy. At our hospital, extended lymphadenectomy is generally not included in routine nephrectomies, but regional lymph node dissection was performed when enlarged or palpable lymph nodes were recognised. The patients were weighed and measured by medical staff at the time of their hospitalisation, before nephrectomy. Body mass index was calculated as weight (kg) divided by the square of the height (m^2^), and expressed as kg m^--2^. All the patients underwent a physical examination, blood evaluation, and chest radiography 3 months, postoperatively, and were examined by computed tomography at 6 months, postoperatively; other radiologic studies were conducted when necessary. If the disease recurred, most patients, before March 2008, received cytokine therapy (interferon alpha or interleukin-2). After the approval of the first targeted molecular agents in April 2008, patients received either cytokine therapy or targeted molecular therapy. Typically, the patients underwent their follow-up examinations at our hospital. Follow-up assessment ended in September 2012. The mean follow-up period was 71 months (range, 1--285 months). Over the course of the investigation, 73 patients had recurrence and 53 died of RCC.

Statistical analyses
--------------------

The end point of this study was cancer-specific survival (CSS). The CSS period was calculated from the date of the nephrectomy to the date of death from the cancer.

The patients were classified using Asian-specific BMI cutoff values (underweight to normal weight, BMI\<23 kg m^--2^; overweight, BMI⩾23 to \<25 kg m^--2^; obese, BMI⩾25 kg m^--2^; [@bib4]). The variables for the different BMI groups were compared using Pearson\'s *χ*^2^ test and analysis of variance; trends were analysed using the Cochran--Armitage test. The correlations among the continuous variables were assessed using Spearman\'s rank analysis. A Cox proportional hazards model was developed to assess the association between CSS and the clinicopathologic variables. Body mass index was included as both a continuous and categorical variable in the Cox regression analyses. Cox multivariate analyses were performed using a forward stepwise variable selection procedure, and survival curves were constructed using the Kaplan--Meier method with the log-rank test. All *P*-values were two-tailed, and *P*-values\<0.05 were considered statistically significant. All statistical analyses were performed using Stata software, version 11 (StataCorp, College Station, TX, USA).

Results
=======

Associations among sex, BMI, and clinicopathologic factors
----------------------------------------------------------

The incidence of RCC demonstrated a male-to-female ratio of 2.7 : 1 for the whole cohort. However, this ratio decreased as the number of women with RCC significantly increased with advancing age (Cochran--Armitage test, *P*=0.010). Men with RCC were found to have a significantly higher mean preoperative BMI (24.0±2.9 kg m^--2^) than women with RCC (22.9±3.3 kg m^--2^; *P*\<0.001; [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Interestingly, whereas BMI decreased, although not significantly, with increasing age in men (*r*=−0.078, *P*=0.164), it significantly increased in women (*r*=0.352, *P*\<0.001; [Figure 1](#fig1){ref-type="fig"}). The incidence of incidentally detected tumours, low nuclear-grade tumours, and low C-reactive protein (CRP) levels, which are frequently observed in obese patients ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}), were examined by sub-analyses by sex. These sub-analyses identified a significant, positive association between BMI and the incidence of both incidentally detected and low nuclear-grade tumours in obese men, only ([Supplementary Tables 3](#sup1){ref-type="supplementary-material"}).

Survival analyses
-----------------

### Whole population analyses

A significant difference in the CSS, by sex, was not observed. The 5-year CSS rate in obese patients was significantly higher than in patients classified into the overweight and underweight to normal weight categories ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The univariate analyses showed that age; presentation mode; tumour size, pT, pN, and M stage; nuclear grade; microscopic venous invasion; Eastern Cooperative Oncology Group Performance Status (ECOG-PS); CRP level; and BMI were significantly associated with CSS ([Table 1](#tbl1){ref-type="table"}). Increased BMI was associated with a higher CSS rate (hazard ratio (HR), 0.888 per kg m^--2^; 95% confidence interval (95% CI), 0.803--0.982; *P*=0.021).

### Sub-population analyses by sex

In men with RCC, the univariate analyses showed that all variables were significantly associated with CSS. The multivariate analysis indicated that BMI as well as T stage, M stage, and nuclear grade were independent predictors of CSS in men with RCC. Conversely, there was no significant association between BMI and CSS in women with RCC (*P*=0.725; [Table 1](#tbl1){ref-type="table"}). The multivariate analysis indicated that pT stage, M stage, nuclear grade, and ECOG-PS were independent predictors of CSS in women with RCC. Further multivariate analyses, including using BMI as a categorical variable instead of a continuous variable, demonstrated that BMI was an independent predictor of CSS only in men with RCC ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). The HRs and 95% CIs for CSS, by BMI category, for men and women are shown in [Figure 2](#fig2){ref-type="fig"}. There was an important sex-related difference in the prognostic value of the patients\' BMI category.

Discussion
==========

This study demonstrated that increased BMI was significantly associated with a favourable prognosis in patients with clear cell RCC and that the mean BMI was significantly lower in women than in men with RCC. In addition, BMI was significantly associated with cancer prognosis in men, but not in women, with RCC.

To date, only two studies have included a description of the associations among sex, BMI, and RCC prognosis. In one study, [@bib6]) retrospectively reviewed the records of 1137 patients with RCC and reported that there was a trend toward better survival with increasing BMI. They also reported that there was no significant survival difference between sexes, based on BMI. Conversely, [@bib17]) reported the results of the Million Women Study, which was a large cohort study conducted in the United Kingdom, investigating cancer incidence and mortality in relation to BMI. Their study demonstrated that increased BMI was associated with increased incidence and mortality associated with kidney cancer in women.

This study demonstrated that increased BMI was associated with incidental and low nuclear-grade tumours in men. Previous studies that have demonstrated an association of increased BMI with a favourable cancer prognosis have also reported an association between increased BMI and low-stage and low-grade tumours ([@bib15]; [@bib11]); however, the underlying mechanism of the association remains unclear. In this study, there was no significant association between BMI and clinicopathologic factors, other than the CRP level in women. This lack of a significant association may be a reason for the sex-related difference in the association of BMI with RCC prognosis.

We also demonstrated that BMI increased with advancing age in women with RCC. In addition, the proportion of female patients increased with advancing age, as reported previously ([@bib8]; [@bib9]). It has been reported that menopause is associated with a progressive gain in body weight and an increased tendency for central adiposity with advancing age ([@bib2]). The change in hormones after menopause may affect the increased incidence of RCC with increasing age in women. These features, specific to women, may also contribute to the difference in the prognostic value of BMI between the sexes. Meanwhile, two previous studies by [@bib6]) and [@bib17]) and this study showed a different result in relation to the association of sex with prognostic value of BMI in kidney cancer patients. Thus, further studies are needed to clarify the nature of this association.

Although this study provides important insights into the clinical implications of BMI in clear cell RCC prognosis, it has several limitations. First, this is a retrospective analysis of data collected from a single institution; hence, the number of cases is relatively small and the ability to extrapolate to a more general population is limited. Second, although the male-to-female ratio in this study is comparable to those in other Japanese studies ([@bib10]; [@bib12]), a male predominance appears to be more prominent in Japan than in Western countries ([@bib6]; [@bib9]). In addition, as shown in this study, the number of patients with metastatic disease at the time of diagnosis is relatively small among Japanese patients compared with Western patients ([@bib10]; [@bib12]). Thus, there may be racial or sociogeographic differences in the baseline characteristics between countries or regions. Third, body weight loss and preoperative nutritional status are also reported to be important prognostic factors in RCC ([@bib3]; [@bib14]). These factors have also been reported to be more important than BMI for determining the prognosis of RCC. However, this study could not include these factors because this information was not available for part of the cohort. Fourth, the Asian-specific BMI cutoff value is different from that for European populations. In addition, the proportion of RCC patients with a BMI⩾25 kg m^--2^ differs between European and Asian studies ([@bib6]; [@bib15]). Further, prospective studies examining the effects of racial and sociogeographic differences are needed to clarify the association of BMI with a sex-based RCC prognosis. On the other hand, to our knowledge, this is the first study to demonstrate sex differences in the prognostic value of BMI for RCC patients. Therefore, we believe that this study provides important insights into the study of BMI in patients with clear cell RCC.

Conclusions
===========

Body mass index was significantly associated with the prognosis for patients with clear cell RCC; however, a sub-population analysis by sex demonstrated that BMI was significantly associated with CSS in men, but not in women. The clinical value of BMI appears to differ between men and women with clear cell RCC.
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![**Correlation between age and body mass index (BMI).** BMI decreased, although not significantly, with increasing age in men (*r*=−0.078, *P*=0.164), but significantly increased with advancing age in women (*r*=0.352, *P*=0.0001).](bjc2013512f1){#fig1}

![**Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for cancer-specific survival by body mass index category.** Patients with a BMI\<23 kg m^--2^ were used as a reference; the HR and 95% CI of overweight (BMI, 23--25 kg m^--2^) and obesity (BMI⩾25 kg m^--2^) are plotted.](bjc2013512f2){#fig2}

###### The results of univariate and multivariate analyses

                                                    **Whole population**   **Male**        **Female**                                                                                                                         
  ------------------ ----------------------------- ---------------------- ---------- ----------------------- --------- ------------ --------- ------------------------ --------- -------- --------- ------------------------- ---------
  Age                         Continuous                   1.034            0.012                                         1.034       0.040                                       1.033     0.193                                  
  Gender                       M *vs* F                    1.404            0.242                                                                                                                                                  
  Presentation        Incidental *vs* symptomatic          4.241           \<0.001                                        4.597      \<0.001                                      3.211     0.020                                  
  Tumour size                 Continuous                   1.259           \<0.001                                        1.299      \<0.001                                      1.198     0.001                                  
  pT stage              1 *vs* 2 *vs* 3 *vs* 4             3.285           \<0.001    2.261 (1.652--3.096)    \<0.001     3.485      \<0.001    2.418 (1.644--3.556)    \<0.001   2.560     0.001     2.718 (1.342--5.507)      0.005
  pN stage               0 or x *vs* positive              9.885           \<0.001                                        9.783      \<0.001                                      8.894     0.004                                  
  M stage                     No *vs* yes                  26.431          \<0.001    8.037 (3.729--17.325)   \<0.001     25.113     \<0.001   11.100 (5.100--24.161)   \<0.001   26.694   \<0.001   23.767 (5.288--106.819)   \<0.001
  Nephrectomy             Partial *vs* total               7.331            0.005                                       565543.080    0.001                                       1.644     0.605                                  
  Nuclear grade               ⩽2 *vs* ⩾3                   12.066          \<0.001    5.051 (2.601--9.808)    \<0.001     14.830     \<0.001   6.687 (2.929--15.265)    \<0.001   8.039    \<0.001    5.162 (1.445--18.437)     0.012
  MVI                         No *vs* yes                  6.005           \<0.001                                        6.415      \<0.001                                      4.648     0.002                                  
  ECOG-PS                      0 *vs* ⩾1                   14.046          \<0.001    2.911 (1.432--5.917)    \<0.001     13.408     \<0.001                                      14.082   \<0.001   10.908 (3.327--35.762)    \<0.001
  CRP (mg dl^--1^)          \<0.3 *vs* ⩾0.3                5.743           \<0.001                                        6.323      \<0.001                                      4.301    \<0.001                                 
  BMI                         Continuous                   0.888            0.021                                         0.822       0.004     0.804 (0.677--0.955)     0.013    1.028     0.725                                  

Abbreviations: BMI-body mass index; CI=confidence interval; CRP, C-reactive protein; ECOG-PS=Eastern Cooperative Oncology Group Performance Status; F=female; HR=Hazard ratio; M=male; MVI=microscopic venous invasion.
